The aim of the study is to determine the safety and tolerability of an autologous CD34+ subset bone marrow stem cell infusion into the middle cerebral artery in patients who have suffered acute total or partial anterior circulation syndrome (TACS/PACS).
The proposed trial will involve the recruitment of a total of 10 patients.
The cells will be collected from each subject recruited, via bone marrow sampling. CD34+ stem cells will then be isolated and harvested during a process of immuno-selection in accordance with the principles of Good Manufacturing Practice. The CD34+ cells will then be directly infused into the area of the stroke intra-arterially using the middle cerebral artery.
Initially, the investigator will monitor each patient for a period of 6 months post-stem cell infusion. Thereafter, they will revert to their previous treatment regime in the clinic.
Assessment of adverse events will be by physical examination and measurement of laboratory parameters. Assessment of efficacy will be by physical examination and the measurement of laboratory, CT and MRI parameters.
- Infusion of autologous CD34+ stem cells into middle cerebral artery Procedure
Intervention Desc: intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
- Allocation: Non-Randomized
- Masking: Open Label
- Purpose: Basic Science
- Endpoint: Safety Study
- Intervention: Single Group Assignment
|Type||Measure||Time Frame||Safety Issue|
|Primary||Safety will be evaluated in terms of adverse events graded according to CTC toxicity criteria and laboratory test results||Duration of study|
|Secondary||Improvement in clinical function as assessed by the Modified Rankin Score, and NIH stroke scale.||Duration of study|